Skip to main content

Advertisement

SpringerLink
Log in

Novel therapies in colon cancer

  • Published:
Current Colorectal Cancer Reports

Abstract

The treatment of metastatic colorectal cancer is currently in transition. The recent advances in treatment provided by bevacizumab and cetuximab have focused research on the development of targeted therapy. This review summarizes the current direction of clinical research and focuses on targeted therapies that are undergoing preclinical and early clinical investigations.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

erences and Recommended Reading

  1. Hynes NE, Lane HA: ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005, 5:341–354.

    Article  PubMed  CAS  Google Scholar 

  2. Cunningham D, Humblet Y, Siena S, et al.: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004, 351:337–345.

    Article  PubMed  CAS  Google Scholar 

  3. Tyagi P: Recent results and ongoing trials with panitumumab (ABX-EGF), a fully human anti-epidermal growth factor receptor antibody, in metastatic colorectal cancer. Clin Colorectal Cancer 2005, 5:21–23.

    PubMed  Google Scholar 

  4. Rothenberg ML, LaFleur B, Levy DE, et al.: Randomized phase II trial of the clinical and biological effects of two dose levels of gefitinib in patients with recurrent colorectal adenocarcinoma. J Clin Oncol 2005, 23:9265–9274.

    Article  PubMed  CAS  Google Scholar 

  5. Keilholz U, Arnold D, Niederle N, et al.: Erlotinib as 2nd and 3rd line monotherapy in patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 2005, 24:A3575.

    Google Scholar 

  6. Janmaat ML, Kruyt FA, Rodriguez JA, Giaccone G: Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways. Clin Cancer Res 2003, 9:2316–2326.

    PubMed  CAS  Google Scholar 

  7. Konecny GE, Pegram MD, Venkatesan N, et al.: Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res 2006, 66:1630–1639.

    Article  PubMed  CAS  Google Scholar 

  8. Zhou Y, Li S, Hu YP, et al.: Blockade of EGFR and ErbB2 by the novel dual EGFR and ErbB2 TKI GW572016 sensitizes human colon carcinoma GEO cells to apoptosis. Cancer Res 2006, 66:404–411.

    Article  PubMed  CAS  Google Scholar 

  9. Fields AL, Rinaldi DA, Henderson CA, et al.: An open label multicenter phase II study of oral lapitinib (GW572016) as a single agent, second-line therapy in patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 2005, 24:A3583.

    Google Scholar 

  10. Calvo E, Tolcher AW, Hammond LA, et al.: Administration of CI-1033, an irreversible pan-erbB TKI, is feasible on a 7-day on, 7-day off schedule: a phase I pharmacokinetic and food effect study. Clin Cancer Res 2004, 10:7112–7120.

    Article  PubMed  CAS  Google Scholar 

  11. Nemunaitis J, Eiseman I, Cunningham C, et al.: Phase 1 clinical and pharmacokinetics evaluation of oral CI-1033 in patients with refractory cancer. Clin Cancer Res 2005, 11:3846–3853.

    Article  PubMed  CAS  Google Scholar 

  12. Yoshimura N, Kudoh S, Kimura T, et al.: EKB-569, a new irreversible epidermal growth factor receptor TKI, with clinical activity in patients with non-small cell lung cancer with acquired resistance to gefitinib. Lung Cancer 2006, 51:363–368.

    Article  PubMed  Google Scholar 

  13. Friess T, Scheuer W, Hasmann M: Combination treatment with erlotinib and pertuzumab against human tumor xenografts is superior to monotherapy. Clin Cancer Res 2005, 11:5300–5309.

    Article  PubMed  CAS  Google Scholar 

  14. Agus DB, Gordon MS, Taylor C, et al.: Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. J Clin Oncol 2005, 23:2534–2543.

    Article  PubMed  CAS  Google Scholar 

  15. LeRoith D, Helman L: The new kid on the block(ade) of the IGF-1 receptor. Cancer Cell 2004, 5:201–202. This manuscript is an excellent review of the IGF-1 receptor and will give readers insight into drug development.

    Article  PubMed  CAS  Google Scholar 

  16. Chakravarti A, Loeffler JS, Dyson NJ: Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. Cancer Res 2002, 62:200–207.

    PubMed  CAS  Google Scholar 

  17. Feng Y, Zhu Z, Xiao X, et al.: Novel human monoclonal antibodies to insulin-like growth factor (IGF)-II that potently inhibit the IGF receptor type I signal transduction function. Mol Cancer Ther 2006, 5:114–120.

    Article  PubMed  CAS  Google Scholar 

  18. Bader AG, Kang S, Zhao L, Vogt PK: Oncogenic PI3K deregulates transcription and translation. Nat Rev Cancer 2005, 5:921–929.

    Article  PubMed  CAS  Google Scholar 

  19. Granville CA, Memmott RM, Gills JJ, Dennis PA: Handicapping the race to develop inhibitors of the phosphoinositide 3-kinase/Akt/mammalian target of rapamycin pathway. Clin Cancer Res 2006, 12:679–689. Inhibitors of the PI3K pathway are viewed by many clinical investigators as the source of the next great therapy for colorectal cancer patients.

    Article  PubMed  CAS  Google Scholar 

  20. Kondapaka SB, Zarnowski M, Yver DR, et al.: 7-hydroxys- taurosporine (UCN-01) inhibition of AktThr308 but not Ser473 phosphorylation: a basis for decreased insulinstimulated glucose transport. Clin Cancer Res 2004, 10:7192–7198.

    Article  PubMed  CAS  Google Scholar 

  21. Ernst DS, Eisenhauer E, Wainman N, et al.: Phase II study of perifosine in previously untreated patients with metastatic melanoma. Invest New Drugs 2005, 23:569–575.

    Article  PubMed  CAS  Google Scholar 

  22. Hideshima T, Catley L, Yasui H, et al.: Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood 2006, In press.

  23. Knowling M, Blackstein M, Tozer R, et al.: A phase II study of perifosine (D-21226) in patients with previously untreated metastatic or locally advanced soft tissue sarcoma: A National Cancer Institute of Canada Clinical Trials Group trial. Invest New Drugs 2006, In press.

  24. Li X, Luwor R, Lu Y, et al.: Enhancement of antitumor activity of the anti-EGF receptor monoclonal antibody cetuximab/C225 by perifosine in PTEN-deficient cancer cells. Oncogene 2006, 25:525–535.

    PubMed  CAS  Google Scholar 

  25. Chan S: Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer. Br J Cancer 2004, 91:1420–1424. MTOR inhibitors are currently in clinical trials and this overview provides excellent insight for clinicians.

    Article  PubMed  CAS  Google Scholar 

  26. Tabernero J, Rojo F, Burris H, et al.: A phase I study with tumor molecular pharmacodynamic (MPD) evaluation of dose and schedule of the oral mTOR-inhibitor Everolimus (RAD001) in patients (pts) with advanced solid tumors. Proc Am Soc Clin Oncol 2005, 24:A3007.

    Google Scholar 

  27. Atkins MB, Hidalgo M, Stadler WM, et al.: Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 2004, 22:909–918.

    Article  PubMed  CAS  Google Scholar 

  28. Chan S, Scheulen ME, Johnston S, et al.: Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. J Clin Oncol 2005, 23:5314–5322.

    Article  PubMed  CAS  Google Scholar 

  29. Shinomiya N, Vande Woude GF: Suppression of met expression: a possible cancer treatment. Commentary re: S. J. Kim et al., reduced c-Met expression by an adenovirus expressing a c-Met ribozyme inhibits tumorigenic growth and lymph node metastases of PC3-LN4 prostate tumor cells in an orthotopic nude mouse model. Clin Cancer Res, 14:5161–5170, 2003. Clin Cancer Res 2003, 9:5085–5090.

    Google Scholar 

  30. Seiden-Long IM, Brown KR, Shih W, et al.: Transcriptional targets of hepatocyte growth factor signaling and Ki-ras oncogene activation in colorectal cancer. Oncogene 2006, 25:91–102.

    PubMed  CAS  Google Scholar 

  31. Smolen GA, Sordella R, Muir B, et al.: Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective TKI PHA-665752. Proc Natl Acad Sci USA 2006, 103:2316–2321.

    Article  PubMed  CAS  Google Scholar 

  32. Matthews N, Visintin C, Hartzoulakis B, et al.: Aurora A and B kinases as targets for cancer: will they be selective for tumors? Expert Rev Anticancer Ther 2006, 6:109–120.

    Article  PubMed  CAS  Google Scholar 

  33. Andrews PD: Aurora kinases: shining lights on the therapeutic horizon? Oncogene 2005, 24:5005–5015.

    Article  PubMed  CAS  Google Scholar 

  34. Warmuth M, Damoiseaux R, Liu Y, et al.: SRC family kinases: potential targets for the treatment of human cancer and leukemia. Curr Pharm Des 2003, 9:2043–2059.

    Article  PubMed  CAS  Google Scholar 

  35. Capobianco AJ, Zagouras P, Blaumueller CM, et al.: Neoplastic transformation by truncated alleles of human NOTCH1/TAN1 and NOTCH2. Mol Cell Biol 1997, 17:6265–6273.

    PubMed  CAS  Google Scholar 

  36. Miele L: Notch signaling. Clin Cancer Res 2006, 12:1074–1079.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Tucker Gosnell Gastrointestinal Cancer Center, Massachusetts General Hospital, 15 Fruit Street, Yawkey 7, 02114, Boston, MA, USA

    David P. Ryan MD

Authors
  1. David P. Ryan MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David P. Ryan MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ryan, D.P. Novel therapies in colon cancer. Curr colorectal cancer rep 2, 116–119 (2006). https://doi.org/10.1007/s11888-006-0029-4

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11888-006-0029-4

Keywords

Search

Navigation